Autopsy report · NCT04517435

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

“Funding unavailable”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Deepa Jagadeesh

Sponsor type

University, hospital or other

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

ME-401; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (98% match in meaning)
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
  “Funding has become unavailable” (96% match in meaning)
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
  “funding became unavailable” (95% match in meaning)
• Protandim and the Metabolic Syndrome
  “funding not available” (95% match in meaning)
• A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
  “Funding no longer available” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.